Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- NEXSCOTIndependent statistical analysis of Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- NEXTIndependent statistical analysis of Novel Executive Function Training for Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03724396).
- Next Generation X-ray Imaging System: Complete Statistical AnalysisIndependent statistical analysis of Next Generation X-ray Imaging System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04571099).
- NEXT2Independent statistical analysis of Efficacy of Esomeprazole in Patients With Frequent Heartburn: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01370538).
- NextCOVEComplete statistical analysis of the phase 3 NextCOVE trial comparing mRNA-1283 with mRNA-1273 for prevention of COVID-19 in participants aged 12 years and older, including non-inferiority methodology, antibody endpoints, COVID-19 efficacy, safety,…
- NEXUSIndependent statistical analysis of Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- NF107-BMP2Independent statistical analysis of A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- NFPIndependent statistical analysis of Nurse-Family Partnership Impact Evaluation in South Carolina: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03360539).
- NGAM-05Independent statistical analysis of High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01313507).
- NGF0112Independent statistical analysis of Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS): Complete Statistical AnalysisIndependent statistical analysis of NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NHiCEIndependent statistical analysis of Northern-Manhattan Hispanic Caregiver Intervention Effectiveness Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02092987).
- NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation: Complete Statistical AnalysisIndependent statistical analysis of NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation: primary endpoint results, effect estimate…
- NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03929913).
- NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial: Complete Statistical AnalysisIndependent statistical analysis of NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NIA-SCOREIndependent statistical analysis of NeuroCognition After Carotid Recanalization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04219774).
- Niacin and Endothelial Function in Early CKD: Complete Statistical AnalysisIndependent statistical analysis of Niacin and Endothelial Function in Early CKD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00852969).
- NIAGARAIndependent statistical analysis of Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- nic_physoIndependent statistical analysis of Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02008292).
- Nicardipine vs Esmolol Craniotomy Emergence: Complete Statistical AnalysisIndependent statistical analysis of Nicardipine vs Esmolol Craniotomy Emergence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01951950).
- NICEIndependent statistical analysis of Neurogenic Intermittent Claudication Evaluation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00905359).
- NICEIndependent statistical analysis of Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02552888).
- NICHEIndependent statistical analysis of N-of-1 Trials In Children With Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03461003).
- NICHEIndependent statistical analysis of Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02089464).
- Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01664741).
- Nicotine Lozenge Bioequivalence Study: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Lozenge Bioequivalence Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01536704).
- Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02532374).
- Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol): Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03369340).
- Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nicotine Reinforcement and Aversion in Young Adult Light Smokers: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Reinforcement and Aversion in Young Adult Light Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01495819).
- Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nicotine Withdrawal Symptoms and Smoking Relapse: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Withdrawal Symptoms and Smoking Relapse: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01511614).
- Nicotine’s Potential Abuse With Menthol: Complete Statistical AnalysisIndependent statistical analysis of Nicotine's Potential Abuse With Menthol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04535362).
- Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02069392).
- Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02312934).
- NICU-TECH RM9L-RS Probe ME Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of NICU-TECH RM9L-RS Probe ME Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01181596).
- Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System: Complete Statistical AnalysisIndependent statistical analysis of Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NIGWVIIndependent statistical analysis of Novel Interventions for GWVI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02661997).
- NIH_HVX6Independent statistical analysis of Chewing and Oral Processing of Solid Food: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05594173).
- NIHO12Independent statistical analysis of Accuracy of Pulse Oximeters With Profound Hypoxia During Motion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04814342).
- NIKAIA 1Independent statistical analysis of To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus: primary endpoint results, effect estimate…
- NILOdeepRIndependent statistical analysis of Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR): Complete Statistical AnalysisIndependent statistical analysis of Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of…
- NIMBLEIndependent statistical analysis of the phase 3 NIMBLE trial (NCT04718389) comparing depemokimab with mepolizumab or benralizumab in severe eosinophilic asthma, including the negative binomial exacerbation rate ratio, non-inferiority logic, ANCOVA secondary endpoints…